Research programme: monoclonal antibodies - Trellis Bioscience

Drug Profile

Research programme: monoclonal antibodies - Trellis Bioscience

Alternative Names: CMV 345; TRL1068

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Trellis Bioscience
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • No development reported Cancer; Cytomegalovirus infections; Respiratory syncytial virus infections; Streptococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Streptococcal-infections in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Cytomegalovirus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top